PMID- 29568959
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200224
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Linking)
VI  - 52
IP  - 5
DP  - 2018 May
TI  - Ethoxysanguinarine inhibits viability and induces apoptosis of colorectal cancer 
      cells by inhibiting CIP2A.
PG  - 1569-1578
LID - 10.3892/ijo.2018.4323 [doi]
AB  - Cancerous inhibitor of protein phosphatase 2A (CIP2A) an endogenous inhibitor of 
      protein phosphatase 2A (PP2A), which can promote proliferation and transformation 
      of several cancer types, has been shown to be a target for tumor therapy. The 
      present study investigated the effects and underlying mechanisms of action of a 
      novel natural compound, ethoxysanguinarine (Eth), on colorectal cancer (CRC) 
      cells. MTT assay and flow cytometric assay found that Eth inhibited the viability 
      and induced the apoptosis of the CRC cells. The inhibition of viability and 
      activation of apoptosis was mediated through the Eth-induced decrease in CIP2A 
      expression. Knockdown of CIP2A by RNA interference sensitized, whereas 
      overexpression of CIP2A antagonized, Eth-induced viability inhibition and 
      apoptosis. Furthermore, western blot analysis suggested that Eth inhibited 
      phosphorylation of CIP2A downstream molecule protein kinase B via the activation 
      of PP2A. CRC xenograft tests also confirmed the antitumor effect of Eth in vivo. 
      These results advance our understanding of Eth-induced viability inhibition and 
      apoptosis, implying the requirement for further investigation of Eth as a CIP2A 
      inhibitor for cancer therapies.
FAU - Jin, Lan
AU  - Jin L
AD  - Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical 
      Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
FAU - Si, Yuan
AU  - Si Y
AD  - Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical 
      Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
FAU - Hong, Xing
AU  - Hong X
AD  - Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical 
      Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
FAU - Liu, Pengfei
AU  - Liu P
AD  - Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical 
      Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
FAU - Zhu, Beibei
AU  - Zhu B
AD  - Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical 
      Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
FAU - Yu, Huiliang
AU  - Yu H
AD  - Hubei Province Key Laboratory of Conservation Biology for Shennongjia Golden 
      Monkey, Administration of Shennongjia National Park, Shennongjia Forestry Region, 
      Hubei 442421, P.R. China.
FAU - Zhao, Xinhua
AU  - Zhao X
AD  - Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical 
      Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
FAU - Qin, Shanshan
AU  - Qin S
AD  - Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical 
      Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
FAU - Xiong, Mengyuan
AU  - Xiong M
AD  - Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical 
      Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
FAU - Liu, Ying
AU  - Liu Y
AD  - Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical 
      Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
FAU - Luo, Zhiguo
AU  - Luo Z
AD  - Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, 
      Shiyan, Hubei 442000, P.R. China.
FAU - Guo, Yang
AU  - Guo Y
AD  - Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical 
      Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20180316
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
SB  - IM
EDAT- 2018/03/24 06:00
MHDA- 2018/03/24 06:01
CRDT- 2018/03/24 06:00
PHST- 2017/10/09 00:00 [received]
PHST- 2018/02/13 00:00 [accepted]
PHST- 2018/03/24 06:00 [pubmed]
PHST- 2018/03/24 06:01 [medline]
PHST- 2018/03/24 06:00 [entrez]
AID - 10.3892/ijo.2018.4323 [doi]
PST - ppublish
SO  - Int J Oncol. 2018 May;52(5):1569-1578. doi: 10.3892/ijo.2018.4323. Epub 2018 Mar 
      16.